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Introductory Editorial
We are pleased to announce this first open access volume
of Clinical Epigenetics following its transfer to BioMed
Central one year after appearance of the first article in
Clinical Epigenetics [1].
Clinical Epigenetics is a peer-reviewed journal, which
publishes original work of exceptional quality and interest,
providing a wide-ranging coverage of research, views, and
reviews on epigenetic principles and mechanisms, and
their effects in relation to human health and disease. Clini-
cal Epigenetics includes epigenetic research in humans
and various disease model organisms, is of interest to the
basic researcher as well as to the physician and clinician.
The journal aims to provide a forum for those interested
in practical questions relating to clinical epigenetics, and
the implications of epigenetics on human health and dis-
ease. Clinical Epigenetics is the official publication of the
Clinical Epigenetics Society [2], a non-profit international
association of physicians, scientists, and interested indivi-
duals with the goal of promoting and supporting scientific
research and communication within the field of clinical
epigenetics. Clinical Epigenetics is the first journal dedi-
cated to the connection of epigenetic patterns to human
physiology and disease.
The transition of Clinical Epigenetics to an open access
publishing model has been made with the intention to
reach out to the continuously increasing audience that
expresses an interest in the field [3-6]. All articles will now
be freely and universally accessible online to a much larger
readership than any subscription-based journal [7]. While
article-processing charges, in the form of a flat fee with no
additional charges for colour figures, movies and large
datasets, apply upon acceptance of a manuscript, all arti-
cles will be available to readers at no cost and will not be
limited by their library’s budget or personal subscriptions,
ensuring that the work published in Clinical Epigenetics is
disseminated within the widest possible audience [7].
The open access publishing model brings a number of
considerable advantages to the journal including better
indexing opportunities, immediate publication upon
acceptance and high visibility within the field. In addition,
we anticipate that the number of online downloads will
continuously increase, as well as the number of citations,
potentially leading to a high citation impact [8,9]. Authors
hold the copyrights for their work and grant anyone the
right to reproduce and disseminate the article, provided
that it is correctly cited and no errors are introduced. In
addition, the journal’s articles are deposited in widely and
internationally recognized open access repositories. This
complies with the policies of a number of funding bodies
including the Wellcome Trust, NIH and Howard Hughes
Medical Institute [10-13]. Particularly in view of recurring
worldwide financial and economic crises that may affect
some countries more than others, it is important to us
that the open access publishing model guarantees that a
country’s economy will not influence its researchers’ ability
to access articles because resource-poor countries (and
institutions) will be able to read the same material as weal-
thier ones [14].
We are delighted to be taking Clinical Epigenetics for-
ward with BioMed Central, and look forward to its success
as an open access journal, providing an international
forum for the latest epigenetics research relating to human
health and disease.
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